title: Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
abstract: Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality, and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD, and current guidelines for management of these patients are largely based on these trials. We aim to review the safety and efficacy of these drugs in patients with CKD presenting with ACS.
authors.affiliation: Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Sukhdeep S
authors.initials: SS
authors.lastname: Basra
authors.forename: Peter
authors.initials: P
authors.lastname: Tsai
authors.forename: Nasser M
authors.initials: NM
authors.lastname: Lakkis
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy*; D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006629:Hirudins / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects; D000068799:Prasugrel Hydrochloride; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects; D000077486:Ticagrelor; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014511:Uremia / Q000150:complications
chemical_list: D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011134:Polysaccharides; D011994:Recombinant Proteins; D013876:Thiophenes; D006493:Heparin; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000077425:Fondaparinux; D000241:Adenosine; D013988:Ticlopidine; D001241:Aspirin; C074619:bivalirudin